MIVetsCan: Cannabidiol (CBD)-Care Trial

Kevin Boehnke

Status and phase

Enrolling

Phase 2

Conditions

Pain, Chronic

Treatments

Drug: Placebo

Drug: Cannabidiol

Study type

Interventional

Funder types

Other

Identifiers

NCT06213233

VMR2022-03 (Other Identifier)

HUM00231202

Details and patient eligibility

About

This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain.

Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period.

The study hypotheses:

CBD would improve overall pain symptoms compared to placebo

Enrollment

468 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures
Armed Services Veteran
All participants must have been enrolled in the MIVetsCan Pain Registry (HUM00223894) for at least 4 weeks and agree to continue participation in that study.
Reports moderate to severe chronic pain defined by protocol
Currently using or interested in using cannabis for pain management
Self-reported willingness to refrain from or not increase current Tetrahydrocannabinol (THC) or other cannabis product use (including CBD) during the study intervention or other cannabinoid use during the study intervention
Individuals of reproductive potential must agree to use acceptable birth control per protocol
Participants must also agree not to donate sperm or eggs during study drug administration
Willingness to attend all study visits (may be done virtually)
Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen
Willingness to wear Fitbit or other similar sensor for passive-data collection
Willingness to fill out daily diary via smartphone to assess symptom status, study drug use, and other cannabis use

Exclusion criteria

Not an Armed Services Veteran
Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English)
Participant reports pregnancy or are nursing
Planning to move out of a state with legal recreational marijuana use during course of study
Risk for imminent harm - Suicidal ideation or wish to die as assessed per protocol
Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
Participation in any other clinical trials over the course of this study
Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)
Having a serious or unstable hepatic disease (e.g., non-alcoholic fatty liver disease or liver cirrhosis)
Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, and seizures
Recent/new diagnosis of cancer within the past 3 years (other than localized melanoma, localized basal cell carcinoma, localized squamous cell carcinoma treated or untreated)
Current valproate and clobazam use per self-report or medical records
Self-reported allergies to sesame oil or cannabis/cannabinoids